Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol Effect on Portosystemic Gradient in Cirrhosis
NCT06861075Recruiting
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of carvedilol in Portal Hypertension (PH), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Percentage of participants with a reduction of at least 10% in the porto-systemic gradient at 1 month. Started Apr 2025; status: recruiting.
02
Drugs
carvedilol
03
Conditions
Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT06861075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861075.